The Journal of the Polish Biochemical Society
and of the Committee of Biochemistry and Biophysics
Polish Academy of Sciences

Acta Biochimica Polonica
Vol. 61 No. 3/2014

Acta Biochimica Polonica
Supplement 1, 2014
BIO 2014 Congress

Selected Review from the Current Issue:

Antivirals - current trends in fighting influenza

Ewelina Król, Małgorzata Rychłowska and Bogusław Szewczyk1

 Influenza virus infection is a major source of morbidity and mortality worldwide. Due to the variable effectiveness of existing vaccines, especially in the early stages of an epidemic, antiviral drugs represent the first line of defense against the virus. Currently, there are two major classes of anti-influenza drugs approved by the FDA for clinical use: M2 protein inhibitors (amantadine and rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir). However, increasing resistance to these available influenza antivirals among circulating influenza viruses highlights the need to develop alternative approaches for the prevention and/or treatment of influenza. This review presents an overview of currently available drugs for influenza treatment as well as summarizes some new antiviral strategies that are now being tested covering agents targeting both the viral proteins and the host-virus interaction. We discuss their mechanisms of action, resistance and the therapeutic potential as new antiviral drug for use in future influenza pandemics. Additionally, combination therapy based on these drugs is also described.

Acta Biochimica Polonica, 61(3), 495-504, Review

Acta Biochimica Polonica is indexed in: Current Contents, Biochem. and Biophys. Citation Index, BIOSIS, Chemical Abstracts, Excerpta Medica, Medline, Index Copernicus, CBR

Acta Biochimica Polonica is a member of the Committee on Publication Ethics (COPE)

Copyright © by Pawel Pomorski and Polish Biochemical Society 2009